A multicentre, randomised, placebo-controlled, double-blind, 4-arm parallel-group, 2-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of GW642444H (100 administered once daily in the morning via DISKUS [TM] dry-powder inhaler) compared with SEREVENT (salmeterol) (50mcg administered twice daily via DISKUS dry-powder inhaler) and placebo in subjects with moderate COPD [chronic obstructive pulmonary disease].

Trial Profile

A multicentre, randomised, placebo-controlled, double-blind, 4-arm parallel-group, 2-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of GW642444H (100 administered once daily in the morning via DISKUS [TM] dry-powder inhaler) compared with SEREVENT (salmeterol) (50mcg administered twice daily via DISKUS dry-powder inhaler) and placebo in subjects with moderate COPD [chronic obstructive pulmonary disease].

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2012

At a glance

  • Drugs Salmeterol; Vilanterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Most Recent Events

    • 11 May 2010 Actual end date (May 2007) added as reported by ClinicalTrials.gov.
    • 11 May 2010 Actual patient number (71) added as reported by ClinicalTrials.gov.
    • 15 Oct 2008 Actual start date changed from Sep 2006 to Nov 2006 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top